What kind of medicine is Delamanid/Delba? Introduction to pharmacology and uses

Delamanid (Delamanid) is a new oral anti-tuberculosis drug used to treat multidrug-resistant tuberculosis (MDR-TB). As the global problem of tuberculosis drug resistance intensifies, traditional first-line drugs such as isoniazid and rifampicin gradually become ineffective in some patients, and the treatment of drug-resistant tuberculosis has become a major public health challenge. The development and application of delamanid provides clinicians with a new treatment option and occupies an increasingly important position in the global anti-tuberculosis drug system.

From a pharmacological perspective, delamanid belongs to the nitroimidazole class of anti-tuberculosis drugs. It inhibits the formation of methoxy-ergosterol in the cell wall synthesis of Mycobacterium tuberculosis, causing the cell wall structure of the pathogenic bacteria to be unable to maintain its integrity, thereby inhibiting its growth and ultimately killing it. This mechanism of action is different from traditional tuberculosis drugs, making delamanid still active against highly drug-resistant strains, which is one of the reasons why it is positioned as a key drug in the treatment of multi-drug-resistant tuberculosis.

The clinical use of delamanid is mainly in combination therapy. Typically, it is not used alone but rather in combination with other effective anti-tuberculosis drugs to form multi-drug combinations to reduce the risk of drug resistance and improve cure rates. Due to the complex condition and long course of treatment of drug-resistant tuberculosis patients, the application of delamanid improves the effectiveness and tolerability of the regimen and provides patients with more treatment opportunities. In some studies, patients' sputum negative conversion rate significantly increased after receiving delamanid's combination regimen, suggesting that the drug can accelerate infection control.

In terms of convenience of use, delamanid is an oral preparation, which improves compliance for tuberculosis patients who require long-term treatment and reduces the discomfort and difficulty of care caused by injectable drugs. At the same time, it is generally well tolerated, with common adverse reactions including gastrointestinal discomfort and mild electrocardiogram changes, most of which can be controlled through clinical monitoring and dose adjustment.

Reference: https://go.drugbank.com/drugs/DB11637